Rexahn Pharmaceuticals (RNN) Stock Price Down 29.3%
Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN)’s share price traded down 29.3% during mid-day trading on Wednesday . The stock traded as low as $1.14 and last traded at $1.18. 2,694,748 shares changed hands during trading, an increase of 885% from the average session volume of 273,630 shares. The stock had previously closed at $1.67.
Several equities research analysts have recently commented on RNN shares. B. Riley started coverage on Rexahn Pharmaceuticals in a research note on Tuesday, July 31st. They set a “buy” rating and a $7.50 price target on the stock. HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Ifs Securities raised Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, October 4th. Finally, Zacks Investment Research raised Rexahn Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.92.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03.
About Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.